Sujet: [Fwd: CANCER from implantable microCHIPS...]
De: Jacques Fortier
Date: Mon, 10 Sep 2007 06:56:30 -0400
A: Marc Côté

-------- Message d'origine --------
Sujet: CANCER from implantable microCHIPS...
Date: Sun, 9 Sep 2007 07:04:40 -0500
De: Russ Rosser <>
A: undisclosed-recipients:;

September 8, 2007

Damning research findings could spell the end of VeriChip

The Associated Press will issue a breaking story this weekend revealing
that microchip implants have induced cancer in laboratory animals and
dogs, says privacy expert and long-time VeriChip opponent Dr. Katherine

As the AP will report, a series of research articles spanning more than
a decade found that mice and rats injected with glass-encapsulated RFID
transponders developed malignant, fast-growing, lethal cancers in up to
1% to 10% of cases. The tumors originated in the tissue surrounding the
microchips and often grew to completely surround the devices, the
researchers said.

Albrecht first became aware of the microchip-cancer link when she and
her "Spychips" co-author, Liz McIntyre, were contacted by a pet owner
whose dog had died from a chip-induced tumor. Albrecht then found
medical studies showing a causal link between microchip implants and
cancer in other animals. Before she brought the research to the AP's
attention, the studies had received little public notice.

A four-month AP investigation turned up additional documents, several of
which had been published before VeriChip's parent company, Applied
Digital Solutions, sought FDA approval to market the implant for humans.
The VeriChip received FDA approval in 2004 under the watch of then
Health and Human Services Secretary Tommy Thompson who later joined the
company's board.

Under FDA policy, it would have been VeriChip's responsibility to bring
the adverse studies to the FDA's attention, but VeriChip CEO Scott
Silverman claims the company was unaware of the research.

Albrecht expressed skepticism that a company like VeriChip, whose
primary business is microchip implants, would be unaware of relevant
studies in the published literature.

"For Mr. Silverman not to know about this research would be negligent.
If he did know about these studies, he certainly had an incentive to
keep them quiet," said Albrecht. "Had the FDA known about the cancer
link, they might never have approved his company's product."

Since gaining FDA approval, VeriChip has aggressively targeted diabetic
and dementia patients, and recently announced that it had chipped 90
Alzheimer's patients and their caregivers in Florida. Employees in the
Mexican Attorney General's Office, workers in a U.S. security firm, and
club-goers in Europe have also been implanted.

Albrecht expressed concern for those who have received a chip implant,
urging them to get the devices removed as soon as possible.

"These new revelations change everything," she said. "Why would anyone
take the risk of having a cancer chip in their arm?"



CASPIAN (Consumers Against Supermarket Privacy Invasion and Numbering)
is a grass-roots consumer group fighting retail surveillance schemes
since 1999 and irresponsible RFID use since 2002. With thousands of
members in all 50 U.S. states and over 30 countries worldwide, CASPIAN
seeks to educate consumers about marketing strategies that invade their
privacy and encourage privacy-conscious shopping habits across the
retail spectrum.

Join us!


Dr. Katherine Albrecht
Founder and Director, CASPIAN Consumer Privacy

Host of "Uncovering the Truth"
We the People Radio Network, M-F 10AM-12PM EST
Listen live:

Co-author of "SPYCHIPS: How Major Corporations and Government
Plan to Track Your Every Move with RFID"

Human Chipping:
Shopper Cards:
Bio online at:


CASPIAN: Consumers Against Supermarket Privacy Invasion and Numbering
Opposing supermarket loyalty cards and other retail surveillance
schemes since 1999

You're welcome to duplicate and distribute this message to others who
may find it of interest.


To subscribe or unsubscribe to the Caspian-newsletter-l mailing list,
the following link or copy and paste it into your browser:

If you have difficulty with the web-based interface, you may also
subscribe or unsubscribe via email by writing to: